Experienced in Hyperparathyroidism

Hong C. Shen

West Lake Rd 38, 
Hangzhou, CN 
Experienced in Hyperparathyroidism
West Lake Rd 38, 
Hangzhou, CN 
OverviewLocationsClinical Research

Overview

Hong Shen practices in Hangzhou, China. Ms. Shen is rated as an Experienced expert by MediFind in the treatment of Hyperparathyroidism. Her top areas of expertise are Parathyroid Cancer, Parathyroid Adenoma, Colitis, Reconstructive Urology Surgery, and Parathyroidectomy.

Her clinical research consists of co-authoring 1000 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 5 articles in the study of Hyperparathyroidism.

Gender
Female

Locations

West Lake Rd 38, Hangzhou, 310009, China
Other Locations
87 Xiangya Road, Changsha, 410008, China
No. 155. Hanzhong Road, Nanjing, 210029, China
No. 28 Fuxing Rd, Beijing, 100853, China
No. 264, Guangzhou Road, Nanjing, China
Building 5, No. 371, Lishizhen Road, Shanghai, 201203, China
No. 759 Erhuan East Road, Huzhou, 313000, China
197, Rui Jin Er Rd, Shanghai, 200025, China
720 Cai Lun Road, Shanghai, 201203, China
Department Of Otorhinolaryngology Head And Neck Surgery, Beijing, China
Number 20, Third Section Of People's South Road, Chengdu, 610000, China
Yihuan Road, Chengdu, 610065, China
No.88 Jiefang Road, Hangzhou, 310009, China
600 Yishan Rd, Shanghai, 200233, China
600 Yishan Road, Shanghai, 200233, China
483 Wushan Road, Guangzhou, 510642, China
720 Cailun Road, Shanghai, 201203, China
23 Youzheng Street, Harbin, 150001, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Prospective, Multicenter, Single-arm, Observational Study to Evaluate the Safety and Effectiveness of Vedolizumab in Real-World Clinical Practice in China
A Prospective, Multicenter, Single-arm, Observational Study to Evaluate the Safety and Effectiveness of Vedolizumab in Real-World Clinical Practice in China
Enrollment Status: Completed
Publish Date: July 22, 2024
View 3 Less Clinical Trials

1000 Total Publications

B2Pin2-enabled reductive thioesterification of aryl triflates with thiocarbonates.
B2Pin2-enabled reductive thioesterification of aryl triflates with thiocarbonates.
Journal: Chemical communications (Cambridge, England)
Published: September 30, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Shen's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 21 Advanced Conditions
    View All 154 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile